Search

Your search keyword '"Ellis, Georgiana"' showing total 126 results
Start Over Author "Ellis, Georgiana"
126 results on '"Ellis, Georgiana"'

1. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

Author

Symonds, Lynn, Jenkins, Isaac, Linden, Hannah M, Kurland, Brenda, Gralow, Julie R, Gadi, Vijayakrishna (V.K.), Ellis, Georgiana K, Wu, Qian, Rodler, Eve, Chalasani, Pavani, Chai, Xiaoyu, Riedel, Jinny, SCCA Network Investigators, Stopeck, Alison, Brown-Glaberman, Ursa, and Specht, Jennifer M

Published
2022
Full Text
View/download PDF

2. Data from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Legend from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 1A-B from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

10. HER-2 testing in breast cancer using parallel tissue-based methods

Author

Yaziji, Hadi, Goldstein, Lynn C., Barry, Todd S., Werling, Robert, Hwang, Harry, Ellis, Georgiana K., Gralow, Julie R., Livingston, Robert B., and Gown, Allen M.

Subjects
Breast cancer -- Diagnosis, Epidermal growth factor -- Testing
Abstract

The HER-2 oncoprotein is overexpressed in 20% to 30% of invasive breast tumors, and its presence confers important prognostic information. Accurate testing for HER-2 in breast cancer can be achieved using immunohistochemistry with complementary fluorescence in situ hybridization (FISH) testing, taking advantage of the strength of each of these technologies.

Published
2004

17. Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer

Author

Ellis, Georgiana and Livingston, Robert B.

Subjects
Breast cancer -- Adjuvant treatment, Fluorouracil -- Dosage and administration, Doxorubicin -- Dosage and administration, Cyclophosphamide -- Dosage and administration, Health
Abstract

Background. Several studies support the belief that the efficacy of adjuvant chemotherapy in breast cancer is related to the dose intensity of the chemotherapy used (expressed in milligrams per square meter per week). Retrospective analyses indicate that the actual delivered dose intensity may correlate more strongly with efficacy than the intended dose delivery. Methods. A doxorubicin-based adjuvant regimen was studied for breast cancer. It was modeled on the Southwest Oncology Group's regimen of cyclophosphamide, methotrexate, and 5-fluorouracil in that daily oral cyclophosphamide and weekly intravenous 5-fluorouracil were used, but weekly doxorubicin was substituted for methotrexate and administered in both the adjuvant and neoadjuvant setting to 29 patients. Results. The actual dose delivery was 1.21-1.24-fold that calculated for the delivered dose in the two other adjuvant regimens using the same three drugs (5-fluorouracil, doxorubicin, and cyclophosphamide) for which this could be determined. This regimen was tolerated well. Toxicity was minimal and consisted largely of expected neutropenia. Conclusions. Whether improved dose intensity can be increased further with the use of growth factors or actually confers improved outcomes awaits the results of larger future trials. Cancer 1993; 71:392-6.

Published
1993

18. Cisplatin and novobiocin in the treatment of non-small cell lung cancer: a Southwest Oncology Group study

Author

Ellis, Georgiana K., Crowley, John, Livingston, Robert B., Goodwin, John W., Hutchins, Laura, and Allen, Ace

Subjects
Antibiotics -- Usage, Cisplatin -- Evaluation, Lung cancer, Health
Abstract

Novobiocin is an antibiotic that works by inhibiting (stopping the action of) a bacterial enzyme involved in the maintenance of DNA (genetic material). Novobiocin also inhibits an enzyme in human cells as well. Experiments in tissue culture have indicated that the inhibition of this enzyme, called DNA topoisomerase II, actually potentiates the action of some anticancer drugs, including cisplatin. In some preliminary studies, it seemed that the addition of novobiocin to chemotherapeutic regimens containing cisplatin might improve the response of lung cancer patients to treatment. As the study involved only a small number of patients, it is important to test this drug combination in a larger and more reliable study. However, the completion of such a study provides no reason to believe that this drug combination provides any useful benefit. A total of 36 patients with non-small cell lung cancer were treated. No complete responses were achieved and only three partial responses were observed. The midpoint survival time of the patients was less than seven months, which is no better than could be achieved using cisplatin alone. At present, novobiocin is available as capsules which are taken orally. Better results might be achieved if it were possible to administer novobiocin to the patients intravenously. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

19. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers

Author

Moe, Roger E., Moe, Kris S., Porter, Peggy, Gown, Allen M., Ellis, Georgiana, and Tapper, David

Subjects
Epidermal growth factor -- Evaluation, Oncogenes -- Evaluation, Breast cancer -- Genetic aspects, Health
Abstract

Her-2/neu protein producft was immunocytochemically analyzed in 139 breast cancers. Epidermal growth factor receptors were similarly analyzed in 74 breast cancers from the same patient pool. These results were also separated on the basis of estrogen receptor proteins and of combined aneuploidy with elevated S-phase from flow cytometry. Invasive breast cancer yielded a positive label for Her-2/neu protein (26%) and for epidermal growth factor receptor (25%), with no significant difference. Correlations with estrogen receptor labeling yielded differences significant inversely for both Her-2/neu protein (p, The biology of growth factors and oncogenes is an active area of breast cancer research. Oncogenes are variants of normal cell genes which under certain conditions have the ability to change normal cells into cancer cells. Expression of one oncogene, Her-2/neu, in the tumor has been linked to higher than expected rates of breast cancer recurrence and mortality. The level of epidermal growth factor found in the fluid in macrocysts (large breast cysts) has been correlated with other factors of increased risk for future breast cancer. The clinical features of epidermal growth factor have not been extensively studied. A study was undertaken on 139 breast cancer patients; all specimens were analyzed for Her-2/neu, and 74 of these were also analyzed for epidermal growth factor receptors. Invasive cancers showed no significant difference between Her-2/neu and epidermal growth factor receptor; both factors were inversely related to hormone (estrogen) receptor status. Epidermal growth factor receptor status seemed to identify a group of breast cancers with a worse prognosis than did Her-2/neu labeling. When epidermal growth factor receptor and Her-2/neu protein were both found in the same cancer, there was usually a poor prognosis. These findings suggest that epidermal growth factor receptor study provides additional information regarding prognosis to that available from identification of Her-2/neu level, meaning that the information supplied by these two analyses is not redundant. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

22. NCCN Guidelines Insights: Antiemesis, Version 2.2017

Author

Berger, Michael J., primary, Ettinger, David S., additional, Aston, Jonathan, additional, Barbour, Sally, additional, Bergsbaken, Jason, additional, Bierman, Philip J., additional, Brandt, Debra, additional, Dolan, Dawn E., additional, Ellis, Georgiana, additional, Kim, Eun Jeong, additional, Kirkegaard, Steve, additional, Kloth, Dwight D., additional, Lagman, Ruth, additional, Lim, Dean, additional, Loprinzi, Charles, additional, Ma, Cynthia X., additional, Maurer, Victoria, additional, Michaud, Laura Boehnke, additional, Nabell, Lisle M., additional, Noonan, Kim, additional, Roeland, Eric, additional, Rugo, Hope S., additional, Schwartzberg, Lee S., additional, Scullion, Bridget, additional, Timoney, John, additional, Todaro, Barbara, additional, Urba, Susan G., additional, Shead, Dorothy A., additional, and Hughes, Miranda, additional

Published
2017
Full Text
View/download PDF

23. Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer.

Author

Specht, Jennifer M., primary, Peterson, Lanell, additional, Novakova, Alena, additional, O'Sullivan, Janet N, additional, O'Sullivan, Finbarr, additional, Shields, Andrew, additional, Montgomery, Susan, additional, Linden, Hannah M., additional, Gralow, Julie, additional, Ellis, Georgiana Kehr, additional, Gadi, Vijayakrishna K., additional, Barlow, William E., additional, Doot, Robert K, additional, Schubert, Erin K, additional, Dunnwald, Lisa K, additional, MacDonald, Lawrence, additional, Kinahan, Paul, additional, and Mankoff, David A., additional

Published
2016
Full Text
View/download PDF

24. Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.

Author

Eunpi Cho, Qian Wu, Rubinstein, Lena, Linden, Hannah, Gralow, Julie, Specht, Jennifer, Gadi, Vijayakrishna, and Ellis, Georgiana

Subjects
TRASTUZUMAB, BREAST tumor risk factors, BREAST tumors, CELL receptors, COMBINATION drug therapy, CLINICAL trials, COMBINED modality therapy, DOXORUBICIN, DRUG administration, DRUG toxicity, EXPERIMENTAL design, FEBRILE neutropenia, GRANULOCYTE-colony stimulating factor, ONCOGENES, ORAL drug administration, PACLITAXEL, TUMOR classification, DISEASE incidence, CYCLOPHOSPHAMIDE, THERAPEUTICS
Abstract

Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early-stage breast cancer. Here, we assessed the use of continuous metronomic weekly doxorubicin plus daily oral cyclophosphamide (AC) with continuous GCSF growth factor support for 12 weeks followed by weekly nab-paclitaxel (nP) for 12 weeks. A nonrandomized phase II clinical trial was designed to assess (1) DFS at 2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities. The dosing of A was 24 mg/m2 IV weekly and C was 60 mg/m2 oral daily (with scheduled filgrastim 5mcg/kg 6 days/week); nP, 100 mg/m2 IV weekly. For patients with HER2 + disease, trastuzumab was started during the nP portion of therapy and continued for 12 months. Sixty patients enrolled with a median follow-up of 6 years. Node-positive disease was present in 58% of patients. Receptor categories included hormone receptor positive/HER2 negative (n = 25; 42%); triple negative (n = 19; 32%); or HER2 positive (n = 16; 27%). DFS at 2 years was 93%. Mean dose delivered was greater than 90% for metronomic AC and 88% for nP. Treatment was well tolerated with a 2% incidence of febrile neutropenia. Continuous metronomic AC followed by nP was well tolerated in our patients with comparable DFS to historical controls. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

25. Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.

Author

Rodler, Eve T., primary, Gralow, Julie, additional, Kurland, Brenda F., additional, Griffin, Melissa, additional, Yeh, Rosa, additional, Thompson, John A., additional, Porter, Peggy, additional, Swisher, Elizabeth M., additional, Gadi, Vijayakrishna K., additional, Korde, Larissa A., additional, Linden, Hannah M., additional, Ellis, Georgiana Kehr, additional, Shepherd, Stacie Peacock, additional, Giranda, Vincent L., additional, Chai, Xiaoyu, additional, Hammond, Jeannette, additional, Hibbert, Reina, additional, Askovich, Bojana, additional, and Specht, Jennifer M., additional

Published
2014
Full Text
View/download PDF

27. Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., additional, Peterson, Lanell M., additional, Schubert, Erin K., additional, Gralow, Julie R., additional, Specht, Jennifer M., additional, Ellis, Georgiana K., additional, Lawton, Thomas J., additional, Livingston, Robert B., additional, Petra, Philip H., additional, Link, Jeanne M., additional, Krohn, Kenneth A., additional, and Mankoff, David A., additional

Published
2011
Full Text
View/download PDF

28. PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Author

Dunnwald, Lisa K., primary, Doot, Robert K., additional, Specht, Jennifer M., additional, Gralow, Julie R., additional, Ellis, Georgiana K., additional, Livingston, Robert B., additional, Linden, Hannah M., additional, Gadi, Vijayakrishna K., additional, Kurland, Brenda F., additional, Schubert, Erin K., additional, Muzi, Mark, additional, and Mankoff, David A., additional

Published
2011
Full Text
View/download PDF

29. Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012

Author

Ellis, Georgiana K., primary, Barlow, William E., additional, Gralow, Julie R., additional, Hortobagyi, Gabriel N., additional, Russell, Christy A., additional, Royce, Melanie E., additional, Perez, Edith A., additional, Lew, Danika, additional, and Livingston, Robert B., additional

Published
2011
Full Text
View/download PDF

30. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)

Author

Slovak, Marilyn L., primary, Bedell, Victoria, additional, Lew, Danika, additional, Albain, Kathy S., additional, Ellis, Georgiana K., additional, Livingston, Robert B., additional, Martino, Silvana, additional, Perez, Edith A., additional, Hortobagyi, Gabriel N., additional, Sher, Dorie, additional, and Stock, Wendy, additional

Published
2009
Full Text
View/download PDF

32. Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer: a Southwest Oncology Group Study

Author

Ellis, Georgiana K., Green, Stephanie, Schulman, Susan, Tranum, Bill L., Goldberg, Ronald S., and Livingston, Robert B.

Subjects
Cyclophosphamide -- Health aspects, Breast cancer, Health
Abstract

Research has provided insights into factors associated with a poor prognosis in breast cancer. One such factor is the absence of the estrogen receptor on breast cancer cells (estrogen-receptor-negative); not only does this factor carry a poor prognosis, but it also correlates with other more traditional negative prognostic factors, such as liver metastases (spread of cancer to the liver). Recurrent or disseminated breast cancers are generally treated with a combination of agents, which usually includes doxorubicin, sometimes referred to by its brand name Adriamycin. Although some response may be achieved in 70 to 80 percent of the patients with estrogen-receptor-negative breast cancer, survival is generally poor with less than 5 percent of patients surviving five years after diagnosis. Roughly 20 percent of patients with estrogen-receptor-positive cancer survive five years after diagnosis. To try to improve treatment success for these poor-prognosis patients, high-dose cyclophosphamide was added to intensify chemotherapy; previous studies established that doses of cyclophosphamide as high as 200 milligrams per kilogram (mg per kg) can be tolerated without necessitating bone marrow infusion. Of 45 patients enrolled in the study, 35 were fully evaluable for results. Patients who continued to have progressive disease after initial chemotherapy with 5-fluorouracil, vinblastine, and doxorubicin were removed from the study. Twenty-six patients were treated with high-dose cyclophosphamide (120 mg per kg) and 16 of these patients relapsed, usually at sites of previous metastases. A median survival time of 15 months and an overall response rate of 69 percent indicates that a single cycle of high-dose cyclophosphamide does not provide a significant benefit. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1989

35. Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Author

Dunnwald, Lisa K., primary, Gralow, Julie R., additional, Ellis, Georgiana K., additional, Livingston, Robert B., additional, Linden, Hannah M., additional, Specht, Jennifer M., additional, Doot, Robert K., additional, Lawton, Thomas J., additional, Barlow, William E., additional, Kurland, Brenda F., additional, Schubert, Erin K., additional, and Mankoff, David A., additional

Published
2008
Full Text
View/download PDF

43. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.

Author

Ellis, Georgiana, Bone, Henry, Chlebowski, Rowan, Paul, Devchand, Spadafora, Silvana, Fan, Michelle, and Kim, Dennis

Abstract

Denosumab increased lumbar spine bone mineral density (BMD) versus placebo in a 2-year, randomized, placebo-controlled, phase 3 study of patients with hormone-receptor-positive, non-metastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy. In subgroup analyses at 12 and 24 months, we evaluated factors (duration and type of aromatase inhibitor, tamoxifen use, age, time since menopause, body mass index, T-score) that might influence BMD at the lumbar spine, total hip, femoral neck, and 1/3 radius. Patients were randomized to receive placebo ( n = 125) or 60 mg denosumab ( n = 127) subcutaneously every 6 months. In all subgroups, 12 or 24 months’ treatment with denosumab was associated with larger BMD gains than placebo across multiple skeletal sites. Most increases were statistically significant ( P < 0.05). Twice-yearly administration of denosumab, regardless of patient subgroup or skeletal site, resulted in consistent increases in BMD versus placebo at 12 and 24 months. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

50. Antiemesis.

Author

Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, McNulty R, Nabati L, Todaro B, Urba S, and Yowell S

Subjects
Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Aprepitant, Area Under Curve, Clinical Protocols, Drug Interactions, Humans, Medical Oncology standards, Morpholines adverse effects, Morpholines therapeutic use, Nausea prevention & control, Neoplasms drug therapy, Neoplasms radiotherapy, Neurokinin-1 Receptor Antagonists, Radiotherapy adverse effects, Serotonin 5-HT3 Receptor Antagonists, Vomiting chemically induced, Vomiting physiopathology, Vomiting prevention & control, Antiemetics therapeutic use, Vomiting drug therapy
Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results